189 related articles for article (PubMed ID: 30005936)
21. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
22. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
[No Abstract] [Full Text] [Related]
23. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
[TBL] [Abstract][Full Text] [Related]
26. Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.
Biasco E; Antonuzzo A; Cianci C; Derosa L; Marconcini R; Farnesi A; Galli L
Tumori; 2014; 100(3):e83-6. PubMed ID: 25076257
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Clin Adv Hematol Oncol; 2018 Feb; 16(2):96. PubMed ID: 29741507
[No Abstract] [Full Text] [Related]
28. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
Naoun N; Vano YA
Bull Cancer; 2021 Nov; 108(11):991-993. PubMed ID: 34538614
[No Abstract] [Full Text] [Related]
29. A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma.
Foxx-Lupo WT; Sing S; Alwan L; Tykodi SS
Clin Genitourin Cancer; 2016 Feb; 14(1):e119-21. PubMed ID: 26549824
[No Abstract] [Full Text] [Related]
30. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
31. Rare case of clear cell renal cell carcinoma presenting as a unilateral tonsil lesion.
Ellis SD; Meikle A; Al-Salti W; Sinclair G
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33303501
[TBL] [Abstract][Full Text] [Related]
32. Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report.
Nasso C; Sabbatini R; Baldessari C; Dominici M; Vitale MG
Tumori; 2021 Dec; 107(6):NP33-NP36. PubMed ID: 33526000
[TBL] [Abstract][Full Text] [Related]
33. [A Case of Hydrocephalus Due to Brain Metastasis from Renal Cell Carcinoma Successfully Treated with Axitinib].
Shimura S; Koguchi D; Minamida S; Taoka Y; Iwamura M
Hinyokika Kiyo; 2017 Jan; 63(1):11-14. PubMed ID: 28245539
[TBL] [Abstract][Full Text] [Related]
34. Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib.
Mennitto A; Verzoni E; Peverelli G; Alessi A; Procopio G
Clin Genitourin Cancer; 2018 Jun; 16(3):e521-e523. PubMed ID: 29656939
[No Abstract] [Full Text] [Related]
35. Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Porta C; Imarisio I; Paglino C
Eur Urol; 2008 May; 53(5):1092-3. PubMed ID: 18160205
[No Abstract] [Full Text] [Related]
36. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
37. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
38. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
[TBL] [Abstract][Full Text] [Related]
39. The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases.
Aytekin A; Ciltas A; Sahinli H; Benekli M
J BUON; 2016; 21(1):281-2. PubMed ID: 27061562
[No Abstract] [Full Text] [Related]
40. Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma.
Iacovelli R; Ciccarese C; Mosillo C; Tortora G
Lancet Oncol; 2019 Feb; 20(2):e124. PubMed ID: 30723040
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
